Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 29, 2026
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
View original at globenewswire.comMannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] co…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
The INFLO-1 results represent an important milestone for MannKind's nintedanib DPI program and further validate the potential of the Technosphere platform in pulmonary fibrosis; across Phase 1a and 1b studies, participants have received more than 700 inhalations of nintedanib DPI, including nearly 450 administered to people living with IPF, and cough was not a meaningful barrier to treatment.
60% confidenceAccording to the American Lung Association and GlobalData, there are an estimated 100,000 IPF patients in the U.S., a 20% rise in the last decade, and IPF affects an estimated 1-1.5 million people worldwide.
60% confidence